COMPANY

eXoZymes

HQ: Monrovia, CA source · exozymes.com ↗ · West Coast

Location: Monrovia, CA · source · Oct 15, 2026

Profile checked Oct 10, 2026

Funding and NIH signals

NIH award NIH awarded $1.03M (SBIR Phase II 2R44GM159516-05A1, competing renewal, notice Jun 19, 2026). NIH RePORTER 2R44GM159516-05A1 (Jun 19, 2026)
Evidence (1 event)
- Jun 19, 2026 · NIH RePORTER 2R44GM159516-05A1
  Organization: INVIZYNE TECHNOLOGIES, INC.; City/State: Monrovia, CA; Project number: 2R44GM159516-05A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-19; FY total cost (award amount): 1034289; Administering IC: National Institute of General Medical Sciences; Project title: SimplePath IIB: Pre-clinical development of Cannabinoid analogs; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Jun 17, 2026 Raise Follow-on offering: $5.95M (total, as published), announced Jun 17, 2026. Source: SEC filing. source ↗
Jun 8, 2026 Raise Follow-on offering: $5.33M (total, as published), announced Jun 8, 2026. Source: SEC filing. source ↗
Nov 14, 2024 Raise IPO: $15M (total, as published), announced Nov 14, 2024. Source: SEC filing. source ↗

Raised: $26.3M. Last 2 years.

Jun 17, 2026 Follow-on offering: $5.95M (total, as published), announced Jun 17, 2026. Source: SEC filing. source ↗
Jun 8, 2026 Follow-on offering: $5.33M (total, as published), announced Jun 8, 2026. Source: SEC filing. source ↗
Nov 14, 2024 IPO: $15M (total, as published), announced Nov 14, 2024. Source: SEC filing. source ↗

Form D raises come from the company’s own SEC filing (last 2 years).

2024-11-19 Raise Private raise (SEC Form D): $12K sold; issuer “Invizyne Technologies Inc”. Verified from the SEC filing. SEC filing ↗